Baillie Gifford - CHINA BIOLOGIC PRODS HLDGS I ownership

CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 89 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q2 2018. The put-call ratio across all filers is 1.05 and the average weighting 0.2%.

Quarter-by-quarter ownership
Baillie Gifford ownership history of CHINA BIOLOGIC PRODS HLDGS I
ValueSharesWeighting
Q3 2018$70,569,000
-47.3%
882,105
-34.5%
0.08%
-47.2%
Q2 2018$133,826,000
+23.5%
1,347,282
+0.7%
0.14%
+13.4%
Q1 2018$108,403,000
+2.1%
1,338,314
-0.7%
0.13%
-3.8%
Q4 2017$106,166,000
-13.8%
1,347,795
+1.0%
0.13%
-15.4%
Q3 2017$123,165,0001,334,8200.16%
Other shareholders
CHINA BIOLOGIC PRODS HLDGS I shareholders Q2 2018
NameSharesValueWeighting ↓
VERNIER CAPITAL PARTNERS, LP 137,557$11,142,0006.62%
COMGEST GLOBAL INVESTORS S.A.S. 637,752$51,658,0001.13%
Black Creek Investment Management Inc. 411,525$33,334,0001.09%
Hillhouse Capital Management 618,391$50,090,0000.88%
RUDMAN ERROL M 21,301$1,725,0000.83%
JUPITER ASSET MANAGEMENT LTD 263,705$21,360,0000.65%
York Capital Management Global Advisors, LLC 341,616$27,671,0000.62%
VONTOBEL ASSET MANAGEMENT INC 873,968$71,525,0000.51%
Temasek Holdings (Private) Ltd 990,000$80,190,0000.44%
WASATCH ADVISORS LP 292,216$23,669,0000.31%
View complete list of CHINA BIOLOGIC PRODS HLDGS I shareholders